CD BioGlyco is committed to providing the best solutions for global clients in the field of glycoscience. We provide various Technologies for HMO Production to our clients. Our advanced technology platforms and high-quality services will fully meet your needs.
The oligosaccharide fraction is the third largest constituent of human milk after lactose (Lac) and lipids. Colostrum has been reported to contain 20-23 g/l oligosaccharides whereas mature bovine milk contains 12-15 g/l oligosaccharides. Several biological functions of HMOs, such as prebiotic, anti-adhesion, glycome-modifying, and anti-inflammatory effects, have currently been shown. Some evidence suggests that HMOs protect breastfed infants from pathogenic bacteria, viruses, and toxins. Oligosaccharides containing N-acetylglucosamine have been reported to promote the growth of Bifidobacterium bifidum, thereby acting as soluble receptor analogs to inhibit protozoa and fungi, preventing the interaction of pathogens with epithelial cells during the initial stages of infection.
DFLNnH is a human milk oligosaccharide. The chemical structure is shown in Fig.1.
Fig.1 Chemical structure of DFLNnH. (CD BioGlyco)
CD BioGlyco provides chemical methods to synthesize DFLNnH. The synthetic strategy for the preparation of DFLNnH begins with the construction of linear type 1/type 2 hexasaccharide benzyl glycosides via a stepwise approach starting from the reducing end. The key compound bears appropriate temporary protecting groups GlcN fucosylation positions at two expected positions, as well as the terminal Gal 2-position (p-methoxybenzyl and allyloxycarbonyl, respectively) and other positions. The persistent protecting groups (benzyl, p-chlorobenzyl, benzoyl, phthalimido, or benzylidene) end as reducing protection since the free oligosaccharides are required after deprotection. Two p-methoxybenzyl groups of hexasaccharide benzyl glycosides are removed selectively and the resulting difucosylation of the diol is performed. Deprotection of the resulting product yields DFLNnH.
For the technology of chemical synthesis of oligosaccharides, please refer to Production of HMO by Chemical Methods.
CD BioGlyco also provides advanced HMO Profiling services. We offer mass spectrometry (MS) for DFLNnH analysis. Samples are diluted and defatted by centrifugation. Proteins are precipitated with ethanol, and the resulting glycans are reduced with sodium borohydride. Solid-phase extraction is performed on graphitized carbon columns to remove lactose and salts. After solvent evaporation, the purified DFLNnH is reconstituted and diluted prior to analysis. Analyze the extracted HMOs on a nano-HPLC-time-of-flight (TOF)-MS. Utilize the identification of DFLNnH by accurate mass, retention time, and elution order.
CD BioGlyco aspires to become the trusted solution provider of your first choice. Our professional research teams provide clients with high-quality DFLNnH production services using nano-HPLC-TOF-MS. If you are interested in our services, please contact us for more details without any hesitation.
Reference:
